



- (51) International Patent Classification: Not classified
- (21) International Application Number:
PCT/US2015/025903
- (22) International Filing Date:
15 April 2015 (15.04.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/980,016 15 April 2014 (15.04.2014) US
- (71) Applicants: **COCRYSTAL PHARMA, INC.** [US/US];
1860 Montreal Road, Tucker, Georgia 30084 (US).
EMORY UNIVERSITY [US/US]; Mailstop
1599/001/1AZ, 1599 Clifton Road, NE, 4th Floor, Atlanta,
Georgia 30322 (US).
- (72) Inventors: **COATS, Steven J.**; 1860 Montreal Road,
Tucker, Georgia 30084 (US). **WHITAKER, Richard An-**
thony; 1860 Montreal Road, Tucker, Georgia 30084 (US).

MCBRAYER, Tamara Rosario; 1860 Montreal Road,
Tucker, Georgia 30084 (US). **SHI, Junxing**; 1860
Montreal Road, Tucker, Georgia 30084 (US).
AMBLARD, Franck; 1599 Clifton Road NE, 4th Floor,
Atlanta, Georgia 30322 (US). **ZHANG, Hongwang**; 1599
Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).
ZHOU, Longhu; 1599 Clifton Road NE, 4th Floor, At-
lanta, Georgia 30322 (US). **SCHINAZI, Raymond F.**;
1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322
(US).

(74) Agent: **BRADIN, David**; Andrews Kurth, LLP, 4505 Em-
peror Blvd, Suite 330, Durham, North Carolina 27703
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,

[Continued on next page]

(54) Title: POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS

(57) Abstract: The present invention is directed to compounds, com-
positions and methods for treating or preventing hepatitis C virus
(HCV) infection in human subjects or other animal hosts. The com-
pounds are as also pharmaceutically acceptable, salts, prodrugs, and
other derivatives thereof as pharmaceutical compositions and methods
for treatment or prevention of HCV infection.




FIGURE 1



MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*